GT Biopharma amends 8-K to correct vote tabulation on authorized shares reduction

GT Biopharma, Inc.

Proposal 4 to reduce authorized shares from 750M to 250M passed with 19,568,632 For, 215,253 Against, 141,506 Abstain.
Original filing incorrectly classified Proposal 4 as non-routine; it was routine, allowing broker discretionary votes.
Company plans special stockholder meeting to ratify inclusion of discretionary broker votes in Proposal 4 tabulation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.